X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (52) 52
hgf/c-met (46) 46
c-met (43) 43
humans (38) 38
hgf (29) 29
proto-oncogene proteins c-met - metabolism (27) 27
oncology (26) 26
animals (24) 24
cancer (22) 22
expression (22) 22
metastasis (20) 20
hepatocyte growth-factor (19) 19
hepatocyte growth factor - metabolism (18) 18
kinases (17) 17
cell biology (15) 15
cell line, tumor (15) 15
hepatocyte growth factor (15) 15
tumors (15) 15
angiogenesis (12) 12
mice (12) 12
cancer therapies (11) 11
male (11) 11
mutation (11) 11
signal transduction (11) 11
female (10) 10
gene expression (10) 10
proto-oncogene proteins c-met - genetics (10) 10
apoptosis (9) 9
growth factors (9) 9
medical prognosis (9) 9
biochemistry & molecular biology (8) 8
c-met protein (8) 8
growth (8) 8
hepatocellular carcinoma (8) 8
hgf/c-met signaling pathway (8) 8
invasion (8) 8
met (8) 8
proteins (8) 8
signal transduction - drug effects (8) 8
cabozantinib (7) 7
carcinoma, renal cell - drug therapy (7) 7
cell proliferation - drug effects (7) 7
hepatocellular-carcinoma (7) 7
hgf/c-met signaling (7) 7
lung cancer (7) 7
proliferation (7) 7
renal cell carcinoma (7) 7
tyrosine (7) 7
vascular endothelial growth factor (7) 7
activation (6) 6
antineoplastic agents - pharmacology (6) 6
antineoplastic agents - therapeutic use (6) 6
cells (6) 6
everolimus (6) 6
hepatocyte growth factor - genetics (6) 6
kidney neoplasms - drug therapy (6) 6
liver neoplasms - genetics (6) 6
migration (6) 6
phosphorylation (6) 6
protein kinase inhibitors - therapeutic use (6) 6
research (6) 6
signaling pathway (6) 6
stem cells (6) 6
targeted therapy (6) 6
vegf (6) 6
anilides - therapeutic use (5) 5
carcinoma (5) 5
carcinoma, hepatocellular - genetics (5) 5
care and treatment (5) 5
cell cycle (5) 5
cell movement - drug effects (5) 5
cross-talk (5) 5
deoxyribonucleic acid--dna (5) 5
drug resistance (5) 5
gene amplification (5) 5
immunohistochemistry (5) 5
inhibitor (5) 5
kidney cancer (5) 5
ligands (5) 5
liver (5) 5
liver cancer (5) 5
lung neoplasms (5) 5
neoplasm invasiveness (5) 5
patients (5) 5
pi3k (5) 5
protein-tyrosine kinase (5) 5
pyridines - therapeutic use (5) 5
receptor (5) 5
sunitinib (5) 5
therapy (5) 5
tyrosine kinase (5) 5
xenograft model antitumor assays (5) 5
akt (4) 4
analysis (4) 4
antineoplastic agents - administration & dosage (4) 4
beta-catenin (4) 4
breast cancer (4) 4
carcinoma, non-small-cell lung - drug therapy (4) 4
carcinoma, renal cell (4) 4
carcinoma, renal cell - metabolism (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
Chinese Journal of Pharmaceutical Biotechnology, ISSN 1005-8915, 12/2017, Volume 24, Issue 6, pp. 534 - 540
Journal Article
Experimental Cell Research, ISSN 0014-4827, 10/2018, Volume 371, Issue 1, pp. 63 - 71
Pancreatic stellate cells (PSCs), a pivotal component of the tumor microenvironment, contribute to tumor growth and metastasis. PSC-derived factors are... 
Glycolysis | Pancreatic stellate cells | HGF/c-MET | YAP | HIF-1α | Cancer stem cells | HYPOXIA-INDUCIBLE FACTOR | HIF-1 alpha | FIBROBLASTS | CELL BIOLOGY | INVASION | ONCOLOGY | PATHWAY | YAP/TAZ | INCREASE | C-MET | GROWTH | RESISTANCE | Index Medicus
Journal Article
Journal of Shanghai Jiaotong University (Medical Science), ISSN 1674-8115, 01/2016, Volume 36, Issue 1, pp. 133 - 137
Journal Article
Sibirskij Onkologičeskij Žurnal, ISSN 1814-4861, 02/2016, Volume 1, Issue 4, pp. 80 - 86
The development of castration-resistant prostate cancer is an important problem of modern oncology. The review is focused on the system of growth factors –... 
prostate cancer, neuregulins, HGF, c-Met, ErbB
Journal Article
Oncotarget, ISSN 1949-2553, 2014, Volume 5, Issue 3, pp. 613 - 633
Adipose tissue is a reservoir of Mesenchymal Stem Cells (Adipose-derived Mesenchymal Stem Cells, ASCs), endowed with regenerative properties. Fat graft was... 
Neoangiogenesis | Adipose-derived mesenchymal stem cells (ASCs) | Breast cancer | Microenvironment | HGF/c-met crosstalk | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 61, pp. 103428 - 103436
In preclinical models, c-Met promotes survival of renal cancer cells through the regulation of programmed death-ligand 1 (PD-L1). However, this relationship in... 
PD-L1 | Metastasis | Renal cell carcinoma | C-Met | Primary | CABOZANTINIB | EVEROLIMUS | VEGF | HEPATOCYTE GROWTH-FACTOR | HGF/C-MET | CANCER | CELL BIOLOGY | renal cell carcinoma | metastasis | SIGNALING PATHWAY | SUNITINIB | PROGNOSTIC MARKER | c-Met | primary
Journal Article
Oncology Letters, ISSN 1792-1074, 05/2012, Volume 3, Issue 5, pp. 1124 - 1128
Journal Article
Journal Article
Chinese Herbal Medicines, ISSN 1674-6384, 10/2018, Volume 10, Issue 4, pp. 405 - 410
To investigate the effects of Chinese herbal formula Qinghuofu (QHF) on the migration and invasion of breast cancer MCF-7 cells and its possible molecular... 
migration | breast cancer | invasion | formula QHF | HGF/c-Met signaling pathway
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2016, Volume 114, Issue 3, pp. 269 - 280
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 44, pp. 76722 - 76739
Journal Article
CURRENT DRUG TARGETS, ISSN 1389-4501, 2016, Volume 17, Issue 15, pp. 1747 - 1754
Drug resistance remains an ongoing challenge for the majority of patients treated with inhibitors of the vascular endothelial growth factor (VEGF) pathway, a... 
mouse models | CANCER CELLS | VEGF | syngeneic | ACQUIRED-RESISTANCE | HGF/C-MET | MESENCHYMAL TRANSITION | RENAL-CELL CARCINOMA | SPONTANEOUS METASTASIS | TUMOR RESISTANCE | metastasis | orthotopic | PHARMACOLOGY & PHARMACY | drug resistance | GEMMs | ANTI-VEGF THERAPY | MALIGNANT PROGRESSION
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 07/2019, Volume 15, Issue 21, pp. 2449 - 2462
Over the past 10 years, sorafenib has been the only systemic agent approved for the treatment of patients with unresectable hepatocellular carcinoma. Recently,... 
VEGFR2 | PLACEBO | XL184 | second-line | metastatic | advanced | angiogenesis | TYROSINE KINASE | HGF/C-MET | immune checkpoint inhibitors | cabozantinib | ONCOLOGY | AXL | C-MET | GROWTH | DOUBLE-BLIND | 2ND-LINE TREATMENT | INHIBITOR | MET | third-line | hepatocellular carcinoma
Journal Article